Results 1 to 10 of about 5,551,009 (351)

The inter-link of ageing, cancer and immunity: findings from real-world retrospective study

Immunity & Ageing, 2023
Background Although the concept of declined immune function associated with cancer has been accepted extensively, real-world clinical studies focusing on analysis of the peripheral blood immune changes underlying ageing, immunity and cancer are scarce ...
Xiaomin Fu, Peng Qin, Fanghui Li, Huifang Zhu, Hongqin You, Yong Zhang, Benling Xu, Tiepeng Li, Fang Zhang, Lu Han, Lingdi Zhao, Baozhen Ma, Zibing Wang, Quanli Gao   +13 more
doaj   +1 more source

Lung cancer immunotherapy: progress, pitfalls, and promises

Molecular Cancer, 2023
Lung cancer is the primary cause of mortality in the United States and around the globe. Therapeutic options for lung cancer treatment include surgery, radiation therapy, chemotherapy, and targeted drug therapy.
Aritraa Lahiri, Avik Maji, P. Potdar, Navneet Singh, P. Parikh, B. Bisht, Anubhab Mukherjee, M. Paul   +7 more
semanticscholar   +1 more source

Beyond the immune suppression: the immunotherapy in prostate cancer [PDF]

, 2015
Prostate cancer (PCa) is the second most common cancer in men.Aswell in many other human cancers, inflammation and immune suppression have an important role in their development.We briefly describe the host components that interact with the tumor to ...
Agliano', Anna Maria, Cattarino, Susanna, Collalti, Giulia, Sciarra, Alessandro, Silvestri, Ida   +4 more
core   +11 more sources

A guide to cancer immunotherapy: from T cell basic science to clinical practice

Nature reviews. Immunology, 2020
The T lymphocyte, especially its capacity for antigen-directed cytotoxicity, has become a central focus for engaging the immune system in the fight against cancer.
A. Waldman, Jill M. Fritz, M. Lenardo
semanticscholar   +1 more source

Exhaustion of CAR T cells: potential causes and solutions

Journal of Translational Medicine, 2022
Chimeric antigen receptor (CAR) T cell therapy has attracted attention for its promising therapeutic effects on hematological malignancies. However, there are problems such as relapse during long-term follow-up and limited effect on solid tumors with ...
Taku Kouro, Hidetomo Himuro, Tetsuro Sasada   +2 more
doaj   +1 more source

Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds. [PDF]

, 2020
Hundreds of trials are being conducted to evaluate combination of newer targeted drugs as well as immunotherapy. Our aim was to compare efficacy and safety of combination versus single non-cytotoxic anticancer agents. We searched PubMed (01/01/2001 to 03/
Barkauskas, Donald A, De Melo Gagliato, Débora, Jardim, Denis L, Kurzrock, Razelle, Nikanjam, Mina   +4 more
core   +1 more source

Hypoxia increases melanoma-associated fibroblasts immunosuppressive potential and inhibitory effect on T cell-mediated cytotoxicity

OncoImmunology, 2021
Cancer-associated fibroblasts (CAFs) and hypoxia are central players in the complex process of tumor cell-stroma interaction and are involved in the alteration of the anti-tumor immune response by impacting both cancer and immune cell populations ...
Linda Ziani, Stéphanie Buart, Salem Chouaib, Jerome Thiery   +3 more
doaj   +1 more source

The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications

Cellular & Molecular Immunology, 2020
Immunotherapy has revolutionized cancer treatment and rejuvenated the field of tumor immunology. Several types of immunotherapy, including adoptive cell transfer (ACT) and immune checkpoint inhibitors (ICIs), have obtained durable clinical responses, but
Yuanyuan Zhang, Zemin Zhang
semanticscholar   +1 more source

Correction to: persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1

Journal for ImmunoTherapy of Cancer, 2019
.
Kellie N. Smith, Nicolas J. Llosa, Tricia R. Cottrell, Nicholas Siegel, Hongni Fan, Prerna Suri, Hok Yee Chan, Haidan Guo, Teniola Oke, Anas H. Awan, Franco Verde, Ludmila Danilova, Valsamo Anagnostou, Ada J. Tam, Brandon S. Luber, Bjarne R. Bartlett, Laveet K. Aulakh, John-William Sidhom, Qingfeng Zhu, Cynthia L. Sears, Leslie Cope, William H. Sharfman, Elizabeth D. Thompson, Joanne Riemer, Kristen A. Marrone, Jarushka Naidoo, Victor E. Velculescu, Patrick M. Forde, Bert Vogelstein, Kenneth W. Kinzler, Nickolas Papadopoulos, Jennifer N. Durham, Hao Wang, Dung T. Le, Sune Justesen, Janis M. Taube, Luis A. Diaz Jr, Julie R. Brahmer, Drew M. Pardoll, Robert A. Anders, Franck Housseau   +40 more
doaj   +1 more source

Long-term survival of a patient with microsatellite-stable refractory colorectal cancer with regorafenib and PD-1 inhibitor sintilimab: a case report and review of literature

BMC Gastroenterology, 2021
Background Colorectal cancer (CRC) is the third most prevalent cancer worldwide and poses a serious challenge for clinicians. Previous studies have shown promising results in patients with Microsatellite Stable microsatellite-stable CRC refractory to ...
Yong Zhang, Fang Zhang, Lingdi Zhao, Xiaomin Fu, Yiman Shang, Quanli Gao   +5 more
doaj   +1 more source